On July 1, 2019, USC and UC San Diego reached a settlement in the ongoing Alzheimer’s disease research lawsuit, Regents of the University of California v. Aisen et al.
UC San Diego for more than three decades has built and supported a world-class program in neurosciences and disorders of the brain, with a special focus on Alzheimer’s disease.
UC San Diego researchers and clinicians continue to contribute insights critical for understanding and treating this devastating disorder. Faculty leaders continue to enjoy the robust support of UC San Diego leadership.
We are pleased that we were able to reach a settlement on this important matter.
USC issued the following statement:
USC Statement regarding UC San Diego case
USC believes that transfers of faculty and grants from one academic institution to another should be done in accordance with all applicable laws and guidelines and in a professional manner consistent with the advancement of the science and research.
USC and Dr. Paul Aisen regret that the manner in which Dr. Aisen and members of the ADCS staff left UC San Diego and brought research assets to USC created disruption to UC San Diego. These actions did not align with the standards of ethics and integrity which USC expects of all its faculty, administrators, and staff.
USC is committed to, and wants to be known for, ethics, integrity and the pursuit of academic excellence, and it has already implemented sweeping changes to this end. These standards will apply to all aspects of University operations, including the recruitment and/or transition of faculty members to or from USC. USC regrets that actions in this case fell short of these standards.
USC and Dr. Aisen acknowledge the outstanding work and the ongoing commitment and leadership of the researchers and administration at UC San Diego in the pursuit of cures for Alzheimer’s disease.